FINWIRES · TerminalLIVE
FINWIRES

AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal

By

AstraZeneca (AZN) said Friday its late-stage trial testing Etcamah with palbociclib, a widely used breast-cancer therapy, did not meet its primary goal of improving progression-free survival.

The company said it observed a numerical improvement in first-line treatment of patients with estrogen receptor-positive, HER2-negative advanced breast cancer who had not received any systemic treatment for advanced disease.

The trial compared Etcamah plus palbociclib with an aromatase inhibitor plus palbociclib, AstraZeneca said.

The safety profile of Etcamah in combination with palbociclib was consistent with the known safety profile of each medicine, the company said.

AstraZeneca shares fell 3.3% in after-hours trading.

What else is happening in Wire?

Wire

National Beverage Fiscal Q1 Earnings Fall, Revenue Rises

National Beverage (FIZZ) reported fiscal Q1 earnings late Thursday of $0.50 per diluted share, down from $0.60 a year earlier.One analyst polled by FactSet expected $0.59.Revenue in the three months ended Aug. 1 rose to $330.7 million from $330.5 million a year earlier.One analyst projected $342.1 million.National Beverage shares fell 3% in after-hours trading.

$FIZZ
Wire

Zumiez Q2 Loss Widens, Revenue Falls; Sets Q3 Guidance

Zumiez (ZUMZ) reported Thursday Q2 loss of $0.17 per diluted share, compared with loss of $0.06 a year earlier.Two analysts surveyed by FactSet expected a loss of $0.14.Revenue for the quarter ended Aug. 1 was $209.0 million, down from $214.3 million a year ago.Two analysts expected $212.1 million.The company expects Q3 EPS of $0.00 to $0.10 on revenue of $222 million to $226 million. Two analysts expect EPS of $0.59, if comparable, and revenue of $238 million.Shares of the company fell over 15% in after-hours trading.

$ZUMZ
Wire

Box, OpenAI Launch Integration to Access Enterprise Content in ChatGPT

Box (BOX) entered a collaboration with OpenAI to launch an integration that lets users access and work with business content stored in its platform directly from ChatGPT.The integration can help accelerate clinical research, streamline legal workflows, and support financial analysts reviewing company reports, Box said Thursday in a statement.The feature is available starting Thursday for Box customers, with OpenAI rolling out access to users of ChatGPT's paid tiers over the coming days.Price: $34.10, Change: $-0.39, Percent Change: -1.13%

$BOX